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Abstract
In the present study, we performed a comprehensive analysis to clarify the clinicopathological characteristics of
patients with amyotrophic lateral sclerosis (ALS) that had progressed to result in a totally locked-in state
(communication Stage V), in which all voluntary movements are lost and communication is impossible. In 11
patients, six had phosphorylated TAR DNA-binding protein 43 (pTDP-43)-immunoreactive (ir) neuronal cytoplasmic
inclusions (NCI), two had fused in sarcoma (FUS)-ir NCI, and three had copper/zinc superoxide dismutase (SOD1)-ir
NCI. The time from ALS onset to the need for tracheostomy invasive ventilation was less than 24 months in ten
patients. Regardless of accumulated protein, all the patients showed common lesions in the pallido–nigro–luysian
system, brainstem reticular formation, and cerebellar efferent system, in addition to motor neurons. In patients with
pTDP-43-ir NCI, patients with NCI in the hippocampal dentate granule neurons (DG) showed a neuronal loss in the
cerebral cortex, and patients without NCI in DG showed a preserved cerebral cortex. By contrast, in patients with
FUS-ir NCI, patients with NCI in DG showed a preserved cerebral cortex and patients without NCI in DG showed
marked cerebral degeneration. The cerebral cortex of patients with SOD1-ir NCI was preserved. Together, these
findings suggest that lesions of the cerebrum are probably not necessary for progression to Stage V. In conclusion,
patients with ALS that had progressed to result in communication Stage V showed rapidly-progressed symptoms,
and their common lesions could cause the manifestations of communication Stage V.
Keywords: Amyotrophic lateral sclerosis, Communication Stage V, Totally locked-in state, Pallido-nigro-luysian
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Introduction
Patients with amyotrophic lateral sclerosis (ALS)
dependent on tracheostomy with invasive ventilation (TIV)
use mostly nonverbal communication and find it difficult
to communicate as their muscle weakness progresses. In a
previous study [9], we proposed a classification system for
the communication abilities of patients with advanced ALS
that consists of five stages: Stage I, communicates in
sentences; Stage II, communicates with one-word answers
only; Stage III, communicates with nonverbal yes/no re-
sponses only; Stage IV, occasionally cannot communicate
due to uncertain yes/no responses; and Stage V, cannot
communicate by any means. We also analyzed the rela-
tionship between clinical findings and the prognosis for
communication disturbance [9, 19]. At present, communi-
cation Stage V is indicative of a “totally locked-in state”
[7, 8]. Our previous analysis of 29 autopsies of patients
with ALS who were dependent on TIV showed that
seven patients who progressed to Stage V had begun to
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require TIV significantly earlier than patients who died
in Stage IV or earlier, and the patients who progressed
to Stage V frequently had a family history of ALS and
gene mutation [9]. Further study showed that need for
TIV, impaired oculomotor movement, and becoming
totally quadriplegic within 24 months of ALS onset
were predictors of severe communication impairment.
Therefore, we recommended early detection of impaired
communication and identification of the best methods of
communication [19]. The first neuropathological reports
of two patients with ALS who progressed to Stage V [7]
showed severe multisystem degeneration. By contrast,
Oyanagi et al. [22] reported marked preservation of the
visual and olfactory pathways in patients with ALS who
progressed to Stage V. There are reports of patients
with lesions in their primary motor cortex, but a preserved
cerebral cortex [10, 14, 16, 24]. In contrast, patients with
marked cerebral atrophy due to degeneration of the cere-
bral cortex and white matter have also been reported
[11, 17, 20]. Neuroradiologically, a progressive cerebral
atrophy has been shown in siblings with ALS who car-
ried a mutation in the gene for optineurin (OPTN)
[28]. However, the distribution and characteristics of
the cerebral lesions are unclear. To date, clinicopathol-
ogy of patients with ALS who progressed to communi-
cation Stage V has been reported only in patient reports
[7, 10, 11, 14, 16, 17, 20, 24, 26, 27]. Therefore, in the
present study we performed a comprehensive analysis of
the clinicopathological features and immunohistochemical
characterization of patients with ALS who had progressed
to communication Stage V.
Materials and methods
Patients
By examining medical records, we enrolled 11 (3.4 % of
studied patients with ALS neuropathology) Japanese pa-
tients with ALS who had progressed to Stage V (Table 1),
from among 320 patients with ALS neuropathologically
confirmed at autopsy at the Tokyo Metropolitan Neuro-
logical Hospital between 1980 and 2012 (150 patients),
and in the Department of Pathology Brain Research In-
stitute, Niigata University between 1963 and 2012 (170
patients). No patients had clinical manifestations of ei-
ther cognitive or behavioral impairment before progres-
sing to Stage V. In addition, no patients showed clinical
evidence of anoxia, such as suffocation, artificial ventila-
tor accident, or blood pressure decrease to <80 mmHg
with shock, during their clinical course. Several patients
were reported elsewhere as having ALS that had pro-
gressed to Stage V [7, 10, 16, 17, 20, 24]; however, some of
the older reports did not provide immunohistochemical
characterization of patient specimens. The clinicopatho-
logical features of patients 4 and 11 were previously re-
ported as motor neuron disease [27] and we reevaluated
these patients as having phosphorylated TAR DNA-
binding protein 43 (pTDP-43)-immunoreactive (ir) neuronal
cytoplasmic inclusions (NCI) and copper/zinc superoxide
dismutase (SOD1)-ir NCI respectively. Therefore, we
included them in the present study, and reevaluated the
clinicopathological and immunohistochemical features
of all 11 patients using the same criteria. Of the 11 patients,
six (patients 1–6) had pTDP-43-ir NCI, two (patients 7, 8)
had fused in sarcoma (FUS)-ir NCI, and three (patients
9–11) had SOD1-ir NCI (Table 1). This study was ap-
proved by the Ethical Review Boards of Tokyo Metro-
politan Neurological Hospital and Niigata University.
Histopathology
Specimens from the brain and spinal cord were fixed with
20 % buffered formalin and embedded in paraffin wax.
Loss of neurons or fibers, or both, and gliosis were assessed
in various regions of the nervous system using 10 or 4 μm
sections in hematoxylin and eosin and Klüver–Barrera
stains. When necessary, Bodian and Holzer stains were
additionally used.
For immunohistochemistry, 6 or 4 μm sections were
prepared. Sections from the frontal lobe, temporal lobe,
hippocampus, parietal lobe, occipital lobe, basal ganglia,
thalamus, cerebellum, midbrain, pons, medulla oblongata,
and spinal cord were immunostained for pTDP-43, using
a rabbit polyclonal antibody against pTDP-43 (pS409/410;
CosmoBio, Tokyo, Japan) at a dilution of 1:5000 or 1:8000,
FUS, using a rabbit polyclonal antibody against FUS
(Sigma-Aldrich St. Louis, MO, USA) at a dilution of 1:
2000, SOD1, using a rabbit polyclonal antibody against
SOD1 (Proteintech, Tokyo, Japan) at a dilution of 1:100.
Required sections were immunostained for phosphory-
lated tau protein using the mouse monoclonal antibody
AT8 (Innogenetics, Ghent, Belgium) at a dilution of 1:200,
α-synuclein using a mouse monoclonal antibody against
α-synuclein (Wako, Osaka, Japan) at a dilution of 1:8000
or 1:10,000, and ubiquitin using a rabbit polyclonal
antibody against ubiquitin (Dako, Glostrup, Denmark)
at a dilution of 1:800. Before antibody incubation, sec-
tions were treated by microwaving in citrate-buffered
saline (pH 6.0, 15 min) to unmask antigens. Antibody
binding was visualized using a labeled streptavidin–biotin
immunoperoxidase method. The chromogen and coun-
terstain were diaminobenzidine and hematoxylin, respect-
ively. NCI in each patient was assessed by immunostaining
with pTDP-43, FUS, or SOD1.
We evaluated the degree and extent of the neuronal
loss, gliosis, and NCI semiquantitatively. Degeneration was
assessed as the degree of neuronal loss and gliosis and was
indicated as absent (–), slight (+) (as shown in Fig. 3i), mild
(++) (as shown in Fig. 3e-g), or severe (+++) (as shown in
Fig. 3a-d, h). The frequency of NCI, evaluated at 200X
magnification, was indicated as follows: none (0), no NCI
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Table 1 Clinical characteristics






















1 F 62 104 LE 12 34 33 37 67 TDP-43 [20]
2 F 52 161 UE 12 25 14 76 85 TDP-43
3 F 53 120 B 56 120 120 120 0 TDP-43
4 M 73 78 B 5 na 11 29 49 TDP-43 [27]
patient 2
5 M 60 117 UE 15 31 18 81 36 TDP-43 [7] case 1
6 M 64 57 UE 12 33 33 56 1 TDP-43 [7] case 2
7 F 13 312 LE 18 18 36 120 192 FUS [17]
patient 1
8 M 39 102 LE 24 66 86 102 0 FUS [16]
9 F 38 106 LE 8 9 11 36 70 SOD1 [24]
10 M 57 128 B 21 45 52 84 44 SOD1 [10]
11 M 61 29 UE 5 6 19 28 1 SOD1 [27]
patient 1
mean 52.0 119.5 17.0 38.7 39.4 69.9 47.8
F female, M male, na not available, TDP-43 TAR DNA-binding protein 43, FUS fused in sarcoma, SOD1 copper/zinc superoxide dismutase 1, LE lower extremity, UE upper extremity, B bulbar















across the entire section; rare (1), an average of <2 NCI per
5 fields; occasional (2), an average of 2–10 NCI per 5 fields;
and frequent (3), an average of >10 NCI per 5 fields. For
the semiquantitative analysis, two neuropathologists (K.H.




Except for patient 7 with FUS-ir NCI, all patients had
adult onset ALS (Table 1). The time from ALS onset to
need for TIV was less than 24 months in ten patients,
and 56 months in patient 3 with pTDP-43-ir NCI. All
the patients progressed to have total quadriplegia and
developed overt oculomotor limitation after using TIV.
Development of oculomotor limitation started before or
after they developed total quadriplegia, and the patients
developed vertical gaze palsy followed by horizontal gaze
palsy. Subsequently the patients showed slow eye move-
ment and ultimately became ophthalmoplegic. All the pa-
tients used only eye movement for communication just
before progressing to Stage V.
Macroscopic findings
Brain weight ranged from 610 to 1395 g (mean 1032.3 g)
(Table 2) before formalin fixation. Four patients (patients
1, 2 (Fig. 1b), and 3 with pTDP-43-ir NCI, and 7 with
FUS-ir NCI (Fig. 1a)) showed severe cerebral atrophy,
which was a brain weight of <1000 g. They showed
marked atrophy of both the pons and midbrain. The
brain weight of seven patients (patients 4 (Fig. 1c), 5 and
6 with pTDP-43-ir NCI, 8 with FUS-ir NCI, and 9–11
with SOD1-ir NCI) was >1000 g, and their pons and
midbrain showed mild to moderate atrophy. All patients
showed severe atrophy of the spinal cord and the me-
dulla oblongata. The optic nerve (Fig. 1) and the lateral
geniculate body of all the patients appeared preserved.
Microscopic findings
Table 2 shows the neuropathological findings of the
patients.
Lesions of the motor system
All the patients showed a severe loss of Betz cells. The
other neurons in the motor cortex were mildly decreased
with a few NCI in the patients with mild cerebral atrophy
(patients 4–6, and 8–11). By contrast, the patients with se-
vere cerebral atrophy (patients 1–3, and 7) showed severe
neuronal loss with gliosis and many NCI in layer 2 and
the deeper layer of the motor cortex. Basophilic inclusions
were frequently observed in patient 7 and rarely observed
in patient 8. The pyramidal tract showed severe fiber loss,
although a few small fibers remained in the medullary
pyramid and both the lateral and anterior corticospinal
tract in the spinal cord. The anterior horn of the spinal
cord and the tegmentum of the brainstem including the
hypoglossal nucleus showed severe atrophy (Fig. 2) and
severe neuronal loss with a few NCI in the atrophied
neurons. The facial and the trochlear nuclei, which were
confirmed in patients 3 and 11 showed severe neuronal
loss with gliosis. The oculomotor nucleus showed a differ-
ence in the degree of degeneration. We were not able to
evaluate the exact occurrence of NCI in the lesions, be-
cause of severe neuronal loss.
Lesions of the extrapyramidal motor system and nonmotor
system
Neuronal and fiber loss with gliosis were observed in the
substantia nigra (Fig. 3a–c), globus pallidus (Fig. 3d–f ),
subthalamic nucleus, brainstem reticular formation, cere-
bellar dentate nucleus, superior cerebellar peduncle, red
nucleus, Clarke’s nucleus, and posterior spinocerebellar
tract in all the patients. In particular, the degeneration of
the substantia nigra (Fig. 3a–c), globus pallidus (Fig. 3d–f),
subthalamic nucleus, and brainstem reticular formation
(Fig. 2) was moderate or severe in all patients regardless of
the time for progression from Stage V to death, or the type
of accumulated proteins. By contrast, the cerebellar ef-
ferent system, which consists of the cerebellar dentate
nucleus, superior cerebellar peduncle, and red nucleus,
showed mild to moderate degeneration in patients 3, 5,
and 6 with pTDP-43-ir NCI, in patient 8 with FUS-ir
NCI, and in patient 11 with SOD1-ir NCI. The time for
progression from Stage V to death was shorter in these
five patients (0–36 months) than in the other six patients
(44–192 months). The cerebellar afferent system, which
consists of the pontine nuclei and middle cerebellar ped-
uncle, was relatively preserved. However, in patient 8, who
had a p.K510M mutation in the gene for FUS (FUS) [16],
showed severe degeneration in the cerebellar afferent
pathway. Patient 7, who had a p.P525L mutation in FUS
and severe frontal lobe atrophy [17], showed severe degen-
eration in the caudate nucleus and putamen (Fig. 3h) and
moderate degeneration in the globus pallidus (Fig. 3e).
The caudate nucleus and putamen (Fig. 3g, i) were rela-
tively better preserved than the globus pallidus (Fig. 3d, f ),
except for in patient 7. The inferior olivary nucleus in pa-
tients 2 and 10 showed vacuolar degeneration in neurons
and an increase of gemistocytic astrocytes, indicating in-
ferior olivary hypertrophy [5, 10]. For pTDP-43, FUS, and
SOD1, no patients exhibited accumulation of multiple dif-
ferent proteins. AT8 immunostaining of neurofibrillary
tangles revealed a Braak stage of ≤ II [1]. No patients had
α-synuclein-ir structures. In addition, among patients with
pTDP-43-ir NCI, no patients showed displayed ubiquitin-
ir NCI in cerebellar granule cells or hippocampal CA4
subfield neurons.
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Table 2 Neuropathological findings
DEG degeneration assessed degree of neuronal loss and gliosis on the hematoxylin and eosin, and Klüver–Barrera-stained sections
The degeneration was indicated as absent (–); slight (+); mild (++); or severe (+++)
NCI neuronal cytoplasmic inclusions, The NCI was indicated as none (0); rare (1); occasional (2); or frequent (3), yellow means that we were not able to evaluate
the exact occurrence of NCI in the lesions, because of moderate to severe neuronal loss
n not evaluated (or not examined), VPM ventral posterior medial nucleus
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Fig. 1 Coronal sections of the cerebrum at the subthalamic nucleus. a Patient 7 with fused in sarcoma (FUS)-immunoreactive (ir) neuronal cytoplasmic
inclusions (NCI) showed enlargement of the anterior horn of the lateral ventricle, and atrophy of the caudate nucleus, putamen, and frontal lobe,
particularly in the frontal white matter along with a thin corpus callosum. However, the hippocampus and temporal lobe were preserved. b Patient 2
with phosphorylated TAR DNA-binding protein 43 (pTDP-43)-ir NCI showed temporal predominately frontotemporal atrophy. c Patient 4 with
pTDP-43-ir NCI showed no white matter atrophy nor enlargement of the lateral ventricle. The globus pallidus and subthalamic nucleus were
brownish with mild to severe atrophy, while the caudate nucleus and the putamen were relatively preserved in all patients except for patient
7 (a), and the optic nerve was preserved in all patients. (Bar = 2 cm)
Fig. 2 Brainstem and seventh cervical cord at the same magnification respectively. All patients showed marked nerve fiber loss of the brainstem
tegmentum including the brainstem reticular formation and both lateral and anterior funiculus in addition to pyramidal tract, and showed marked
atrophy of the anterior horn of the spinal cord. The medulla oblongata and spinal cords showed severe atrophy and the fourth ventricle was markedly
dilatated with severe degeneration of the hypoglossal nucleus in all patients. The midbrain and pons showed severe atrophy in patients 2
with phosphorylated TAR DNA-binding protein 43 (pTDP-43)-immunoreactive (ir) neuronal cytoplasmic inclusions (NCI) (a) and patient 7 with
fused in sarcoma (FUS)-ir NCI (c) in whom brain weight was less than 1000 g, mild to moderate atrophy in patient 5 with pTDP-43-ir NCI (b),
patient 8 with FUS-ir NCI (d), and patient 10 with copper/zinc superoxide dismutase (SOD1)-ir NCI (e) in whom brain weight was more than
1000 g. The superior cerebellar peduncle in patients 5 (b) and 8 (d) were degenerated mildly. Loss of transverse fibers of the pons and middle
cerebellar peduncle were observed only in patient 8 (d). The posterior column of the spinal cord showed a marked loss of fibers in patients 5
(g) and 10 (j), but they were relatively preserved in patient 7 (h), and fiber loss of the middle root zone in patient 2 (f) and 8 (i). a, f Patient 2
with pTDP-43-ir NCI. b, g Patient 5 with pTDP-43-ir NCI. c, h Patient 7 with FUS-ir NCI. d, i Patient 8 with FUS-ir NCI. e, j Patient 10 with SOD1-ir NCI,
(Bar = 5 mm, Klüver–Barrera staining)
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Preserved areas
The optic tract and optic radiation were well preserved
in all the patients (Fig. 4). The lateral geniculate body
was examined in nine patients, of which eight showed
comparative preservation. In the striate cortex, although
there were a few NCI in six patients (patients 1–4 with
pTDP-43-ir NCI, and patients 7 and 8 with FUS-ir
NCI), mild neuronal loss and gliosis were observed only
in patient 4. The nucleus basalis of Meynert was exam-
ined in eight patients, showing no neuronal loss although
a few NCI were found in patients 4, 6 with pTDP-43-ir
NCI and in patient 11 with SOD1-ir NCI.
Cerebral cortical findings by accumulated protein
Among six patients with pTDP-43-ir NCI (patients 1–6),
four (patients 1–4) had NCI in the hippocampal dentate
granule neurons and showed neuronal loss and gliosis
with NCI in the hippocampal subiculum, and the frontal
and temporal cortex (Fig. 5a–c). Patients 5 and 6, lacking
NCI in the dentate granule neurons in the hippocampus,
demonstrated the occurrence of NCI, limited to the
frontal cortex, in the absence of neuronal loss (Fig. 5d–f ).
The pTDP-43-ir pathological pattern of all six patients
was consistent with type B [12].
One (patient 7) with FUS-ir NCI showed frontal and
temporal cortical degeneration with compacted occurrence
of smaller NCI in the absence of NCI in the hippocampal
dentate granule neurons (Fig. 5g–i). The other (patient 8)
had noncompact NCI in the hippocampal dentate granule
neurons, and their cerebral cortex was preserved with rare
NCI (Fig. 5j–l).
The cerebral cortex, with the exception of the motor
cortex, of all three patients with SOD1-ir NCI was pre-
served. A few NCI were scattered in the temporal cortex
only in patient 9.
Discussion
As noted in our previous reports [9, 19], patients with
ALS that progressed to Stage V showed rapid clinical
Fig. 3 Lesions of the nonmotor system. a–c Substantia nigra showing severe neuronal loss with gliosis. d–f Globus pallidus, g–i putamen. Only
patient 7 showed more severe degeneration in the putamen (h) than in the globus pallidus (e). Other patients showed more severe degeneration in
the globus pallidus (d, f) than in the putamen (g, i). a-d, h neuronal loss and gliosis were severe (+++). e-g neuronal loss and gliosis were mild (++).
i neuronal loss and gliosis were slight (+). a, d, g Patient 2 with phosphorylated TAR DNA-binding protein 43-immunoreactive (ir) neuronal cytoplasmic
inclusions (NCI). b, e, h Patient 7 with fused in sarcoma-ir NCI. c, f, i Patient 10 with copper/zinc superoxide dismutase-ir NCI, (Bar = 50 μm, hematoxylin
and eosin staining)
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deterioration, and tended to need TIV within 24 months
of ALS onset. The onset of lesions varied, and the onset
lesions and the time from onset to resulting in Stage V did
not appear to be related. Subsequently, their condition
progressed to Stage V due to complete ophthalmoplegia
in addition to total quadriplegia. This clinical course is
similar to that of the previously reported patients who
progressed to Stage V (Table 3) [11, 14, 26, 28]. However,
a few patients required TIV over 24 months after the on-
set, such as our patient 3 with pTDP-43-ir NCI, and three
patients reported in the existing literature, showing
pTDP-43-ir NCI [11], basophilic inclusions [14], and a
mutation in OPTN [28], respectively (Tables 1 and 3).
These patients showed that patients who required TIV
after more than 24 months from disease onset could not
necessarily avoid progression to Stage V.
Neuropathologically, regardless of the type of accumu-
lated proteins, all the patients shared the feature of severe
degeneration in the substantia nigra, globus pallidus, sub-
thalamic nucleus, brainstem reticular formation, and mild
to severe degeneration of the cerebellar efferent system, in
addition to the severe degeneration in both upper and
lower motor neurons. It is likely that the constellation of
such lesions is common in patients with ALS who pro-
gress to Stage V, because the patients reported in the lit-
erature who had progressed to Stage V also demonstrated
a similar constellation (Table 3) [11, 14, 26]. In addition,
Miki et al. [13] reported a patient with ALS who required
TIV and did not progress to Stage V, and discussed this
with regard to pallido–nigro–luysian degeneration. They
concluded that the pallido–nigro–luysian degeneration
may be involved in the ALS disease process [13]. Another
patient with ALS who required TIV and did not progress
to Stage V also showed pallido–nigro–luysian degener-
ation [23]. These two patients who did not progress to
Stage V showed no apparent degeneration in the brain-
stem reticular formation or cerebellar efferent system,
although they did show pallido-nigro-luysian degeneration
similar to the patients who progressed to Stage V [13, 23].
Therefore, it is likely that the degeneration of the
brainstem reticular formation and the cerebellar efferent
system in addition to degeneration of the pallido–nigro–
luysian system is necessary for progression to Stage V.
Relatively mild degeneration of the cerebellar efferent
system was seen in patients who died shortly after pro-
gressing to Stage V (patients 3, 5, 6, 8, 11) and has been
reported in one patient [26]. The time for progression
from Stage V to death may alter the degree of degener-
ation in the cerebellar efferent system.
Neuroanatomically, the common lesions of patients with
ALS who progressed to Stage V appeared to be related to
each other through connections with the motor-related
area (Fig. 6) [4]. The degeneration of motor neurons,
which are the basic lesions in ALS, is so severe in patients
who progress to Stage V that the degeneration of asso-
ciated areas appeared to occur secondarily due to de-
generation of motor neurons. We could not evaluate
the precise relationship between neuronal loss and oc-
currence of NCI because of the severe neuronal loss.
Brettschneider et al. described a pTDP-43 staging
Fig. 4 Preserved areas. a Preserved optic tract (arrow) and severe degeneration of the other regions. b Preserved lateral geniculate body (arrow)
and severe degeneration of other regions. (Patient 7, Bar = 5 mm, Klüver–Barrera staining)
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algorithm, and presented evidence for a possible se-
quential dissemination of pTDP-43 pathology [2, 3].
However, applying the stages of pTDP-43 to the present
patients with pTDP-43-ir NCI, the inferior olivary nu-
cleus, which was mentioned as an early lesion [2, 3],
showed relatively mild neuronal loss even in communi-
cation Stage V, and the subthalamic nucleus, which was
mentioned as a lesion having no NCI until late stages
[2, 3], showed moderate to severe degeneration in
communication Stage V. At least in the patients with
pTDP-43-ir NCI, we speculate that the ease of occur-
rence of NCI and the speed of degeneration in the pa-
tients with ALS may differ depending on each lesion, as
follows: (1) Lesions that showed a matched degree of
appearance of NCI and neuronal loss, such as in the
motor neurons, globus pallidus, and substantia nigra, (2)
lesions that had NCI from an early disease phase without
rapid neuronal loss, such as in the inferior olivary
Fig. 5 Immunohistochemical features of cerebral lesions. a–c Patient 2 with phosphorylated TAR DNA-binding protein 43 (pTDP-43)-immunoreactive
(ir) neuronal cytoplasmic inclusions (NCI) in the hippocampal dentate granule neurons (c) had occasional NCI in the frontal (a) and temporal (b) cortex.
d–f Patient 6 without pTDP-43-ir NCI in the hippocampal dentate granule neurons (f) had rare NCIs in the frontal cortex (d) and no NCIs in the
temporal cortex (e). g–i Patient 7 with occasional fused in sarcoma (FUS)-ir NCI in the frontal cortex (g) and rare NCI in the temporal cortex
(h) had no NCI in the hippocampal dentate granule neurons. j–l Patient 8 without FUS-ir NCI in the frontal (j) and temporal cortex (k) had rare
NCI in the hippocampal dentate granule neurons (l). Bar = 50 μm
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nucleus, (3) lesions although having rare NCI in early
disease phases, subsequently showed severe neuronal
loss, such as in the subthalamic nucleus, and (4) lesions
that had rare NCI without obvious neuronal loss, such
as in the lateral geniculate body and striate cortex in the
visual pathway, which were preserved from lesions in
patients who progressed to Stage V [22].
In this study, patient 2 with pTDP-43-ir NCI and patient
10 with SOD1-ir NCI [10] had inferior olivary hypertrophy.
It is noteworthy that inferior olivary hypertrophy can
occurs in ALS, regardless of accumulated protein, likely
to progressive supranuclear palsy [6], Creutzfeldt–Jakob
disease [15], or cerebrovascular disease [5].
A distinct pattern of protein accumulation was found
in the cerebral cortex. First, in patients with pTDP-43-ir
NCI (Table 2, Fig. 5a–f ), patients with no NCI in the
hippocampal dentate granule neurons (patients 5, 6)
showed limited degeneration in the frontal cortex, and
had relatively preserved brain weight. By contrast, pa-
tients with NCI in the hippocampal dentate granule neu-
rons (patients 1–4) showed marked degeneration in the
temporal cortex and hippocampal subiculum; and NCI
were observed in the frontal, temporal, and occipital cor-
tex. The characteristics of the cerebral cortical features
in the present patients could be classified according to
the presence of NCI in the hippocampal dentate granule
neurons as described by Nishihira et al. [21]. Moreover,
we identified that the patient with a Nishihira’s Type 1
distribution pattern also progressed to Stage V. Interest-
ingly, the relationship between NCI in the hippocampal
dentate granule neurons and cerebral cortical
degeneration showed a contrasting trend in patients
with pTDP-43-ir NCI and FUS-ir NCI in this study as
follows: patient 7 [17], who lacked NCI in the hippocam-
pal dentate granule neurons showed severe atrophy of the
cerebrum, whereas patient 8 [16], who had NCI, showed
no atrophy of the cerebrum (Table 2, Fig. 5g–l). Second,
the cerebral cortex of all 3 patients with SOD1-ir NCI
was preserved with rare NCI. Patients with a mutation
in SOD1 were reported as having frontotemporal de-
mentia (FTD) and decline of cognitive function was
rare [25, 29]. Only one patient with a mutation in
SOD1 showing frontotemporal lobar degeneration
(FTLD) underwent a detailed clinicopathological ana-
lysis [18]. Taking these findings together, it is likely that
the cerebrum of patients with SOD1-ir NCI may be pre-
served even in the patients who progressed to Stage V. That
there were three patients who showed a preserved cere-
brum (patients 9–11), and that cerebral lesions shared by
all patients and severe neuronal loss were missing in the
present patients, suggest that cerebral cortical involvement
was not necessary to progress to Stage V.
It is important to differentiate the present patients from
patients showing FTLD. There is a limitation in that the
decline of cognitive function cannot be assessed in the
patients who progressed to Stage V. However, none of
the patients had any clinical manifestation of cognitive
or behavioral impairment while they could communicate,
so they were not diagnosed as having FTD [25]. Further-
more, it was revealed that the patients who progressed to




















Fig. 6 The connections of motor neuron-related area. The common lesion of the ALS patients who progressed to Stage V is emphasized. All the
common lesions related to the motor neurons and pyramidal tract. Shaded areas: lesions that showed moderate or severe degeneration in all the
patients regardless of the time for progression to Stage V to death or type of accumulated protein. Stippled areas: lesions that showed a different
degree of degeneration depending on the time from progression to Stage V to death
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Conclusion
In the present study, we evaluated only a small number of
patients because the patients who progressed to Stage V
were limited to 3.4 % of all patients with ALS who under-
went autopsy. Nevertheless, we identified that the patients
who progressed to Stage V, including the patients reported
previously, had common lesions in the pallido–nigro–luy-
sian system, brainstem reticular formation, cerebellar den-
tate nucleus, superior cerebellar peduncle, and red
nucleus, besides motor neurons. Moreover, we clarified spe-
cific characteristics in the relationship between accumu-
lated protein and the cerebral cortical lesions. Thus, there
may be common lesions that can identify patients with
ALS who progress to Stage V. We consider that attention
to the occurrence of symptoms of the extrapyramidal
motor system and nonmotor system, and a radiological
assessment of common lesions are important for predict-
ing communication disability, especially in the patients
who progressed rapidly from disease onset to TIV.
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